Plasma pentraxin 3 is a more potent predictor of endothelial dysfunction than high-sensitive C-reactive protein

International Heart Journal

Volumn 55, Issue 2, 2014, Pages 160-164

  Yasunaga, Tomohiko ^a   Ikeda, Satoshi ^a   Koga, Seiji ^a   Nakata, Tomoo ^a   Yoshida, Takeo ^a   Masuda, Nobuhito ^b   Kohno, Shigeru ^c   Maemura, Koji ^a  

^a NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

^b Perseus Proteomics   (Japan)

^c NAGASAKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Coronary artery disease; Flow mediated dilation; Inflammation

Indexed keywords

C REACTIVE PROTEIN; CALCIUM ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PENTRAXIN 3;

ADULT; AGED; ARTICLE; BRACHIAL ARTERY; CLINICAL ARTICLE; COMPARATIVE STUDY; CORONARY ARTERY DISEASE; DOPPLER FLOWMETRY; ECHOGRAPHY; ENDOTHELIAL DYSFUNCTION; FEMALE; HUMAN; INFLAMMATION; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL PREDICTION; VASODILATATION;

AGED; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; BRACHIAL ARTERY; C-REACTIVE PROTEIN; CORONARY ARTERY DISEASE; DISEASE PROGRESSION; ENDOTHELIUM, VASCULAR; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; PREDICTIVE VALUE OF TESTS; REGIONAL BLOOD FLOW; RETROSPECTIVE STUDIES; SERUM AMYLOID P-COMPONENT; ULTRASONOGRAPHY, DOPPLER, PULSED; VASODILATION;

EID: 84897068320     PISSN: 13492365     EISSN: 13493299     Source Type: Journal    
DOI: 10.1536/ihj.13-253     Document Type: Article

References (29)

1. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999; 340: 115-26.(Review)
2. Furchgott RF, Vanhoutte PM. Endothelium-derived relaxing and contracting factors. FASEB J 1989; 3: 2007-18. (Review)
3. Zhang L, Gong D, Li S, Zhou X. Meta-analysis of the effects of statin therapy on endothelial function in patients with diabetes mellitus. Atherosclerosis 2012; 223: 78-85. (Review)
4. Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes DR Jr, Lerman A. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 2000; 101: 948-54.
5. Neunteufl T, Heher S, Katzenschlager R, et al. Late prognostic value of flow-mediated dilation in the brachial artery of patients with chest pain. Am J Cardiol 2000; 86: 207-10.
6. Nawawi H, Osman NS, Annuar R, Khalid BA, Yusoff K. Soluble intercellular adhesion molecule-1 and interleukin-6 levels reflect endothelial dysfunction in patients with primary hypercholesterolaemia treated with atorvastatin. Atherosclerosis 2003; 169: 283-91.
7. Araujo JP, Lourenco P, Azevedo A, et al. Prognostic value of highsensitivity C-reactive protein in heart failure: a systematic review. J Card Fail 2009; 15: 256-66. (Review)
8. Fichtlscherer S, Rosenberger G, Walter DH, Breuer S, Dimmeler S, Zeiher AM. Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease. Circulation 2000; 102: 1000-6.
9. Bottazzi B, Doni A, Garlanda C, Mantovani A. An integrated view of humoral innate immunity: pentraxins as a paradigm. Annu Rev Immunol 2010; 28: 157-83. (Review)
10. Deban L, Russo RC, Sironi M, et al. Regulation of leukocyte recruitment by the long pentraxin PTX3. Nat Immunol 2010; 11: 328-34.
11. Corretti MC, Anderson TJ, Benjamin EJ, et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002; 39: 257-65.
12. Celermajer DS, Sorensen KE, Gooch VM, et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992; 340: 1111-5.
13. Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009; 53: 982-92.
14. Lusis AJ. Atherosclerosis. Nature 2000; 407: 233-41. (Review)
15. Cines DB, Pollak ES, Buck CA, et al. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood 1998; 91: 3527-61. (Review)
16. Kullo IJ, Malik AR. Arterial ultrasonography and tonometry as adjuncts to cardiovascular risk stratification. J Am Coll Cardiol 2007; 49: 1413-26. (Review)
17. Hein TW, Singh U, Vasquez-Vivar J, Devaraj S, Kuo L, Jialal I. Human C-reactive protein induces endothelial dysfunction and uncoupling of eNOS in vivo. Atherosclerosis 2009; 206: 61-8.
18. Venugopal SK, Devaraj S, Yuhanna I, Shaul P, Jialal I. Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation 2002; 106: 1439-41.
19. Singh U, Devaraj S, Vasquez-Vivar J, Jialal I. C-reactive protein decreases endothelial nitric oxide synthase activity via uncoupling. J Mol Cell Cardiol 2007; 43: 780-91.
20. Teoh H, Quan A, Lovren F, et al. Impaired endothelial function in C-reactive protein overexpressing mice. Atherosclerosis 2008; 201: 318-25.
21. Guan H, Wang P, Hui R, Edin ML, Zeldin DC, Wang DW. Adenoassociated virus-mediated human C-reactive protein gene delivery causes endothelial dysfunction and hypertension in rats. Clin Chem 2009; 55: 274-84.
22. Verma S, Kuliszewski MA, Li SH, et al. C-reactive protein attenuates endothelial progenitor cell survival, differentiation, and function: further evidence of a mechanistic link between C-reactive protein and cardiovascular disease. Circulation 2004; 109: 2058-67.
23. Savchenko A, Imamura M, Ohashi R, et al. Expression of pentraxin 3 (PTX3) in human atherosclerotic lesions. J Pathol 2008; 215: 48-55.
24. Gustin C, Delaive E, Dieu M, Calay D, Raes M. Upregulation of pentraxin-3 in human endothelial cells after lysophosphatidic acid exposure. Arterioscler Thromb Vasc Biol 2008; 28: 491-7.
25. Morishita T, Uzui H, Nakano A, et al. Number of endothelial progenitor cells in peripheral artery disease as a marker of severity and association with pentraxin-3, malondialdehyde-modifi ed lowdensity lipoprotein and membrane type-1 matrix metalloproteinase. J Atheroscler Thromb 2012; 19: 149-58.
26. Nebuloni M, Pasqualini F, Zerbi P, et al. PTX3 expression in the heart tissues of patients with myocardial infarction and infectious myocarditis. Cardiovasc Pathol 2011; 20: e27-35.
27. Suliman ME, Yilmaz MI, Carrero JJ, et al. Novel links between the long pentraxin 3, endothelial dysfunction, and albuminuria in early and advanced chronic kidney disease. Clin J Am Soc Nephrol 2008; 3: 976-85.
28. Yilmaz MI, Sonmez A, Ortiz A, et al. Soluble TWEAK and PTX3 in nondialysis CKD patients: impact on endothelial dysfunction and cardiovascular outcomes. Clin J Am Soc Nephrol 2011; 6: 785-92.
29. Rolph MS, Zimmer S, Bottazzi B, Garlanda C, Mantovani A, Hansson GK. Production of the long pentraxin PTX3 in advanced atherosclerotic plaques. Arterioscler Thromb Vasc Biol 2002; 22: e10-4.